Endovasc Receives Notice of Allowance for U.S. Patent Protecting Its Muscle Mass Technology.
HOUSTON -- Endovasc Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :EVSC EVSC Evansville Vanderburgh School Corporation , OTC OTC
See over-the-counter market (OTC). : EVSD), today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office for its pending patent application entitled "Development of Muscle Mass in a Mammal". The patent covers the use of the Company's non-steroidal supplement technology for muscle cell recruiting and accelerated bodybuilding bodybuilding
Developing of the physique through exercise and diet, often for competitive exhibition. Bodybuilding aims at displaying pronounced muscle tone and exaggerated muscle mass and definition for overall aesthetic effect. and strengthens Endovasc's nutraceutical intellectual property portfolio currently incorporated in the Endothil-CR product marketed by Basic Research.
"This patent adds a new layer to our Company's broad intellectual property portfolio and demonstrates Endovasc's innovation in the field of nutraceuticals. We are committed to commercializing our pipeline of nutraceutical products. Patent protection such as this is critical for ensuring Endothil-CR's exclusivity in the marketplace," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer.
Endovasc's wholly owned subsidiary Wholly Owned Subsidiary
A subsidiary whose parent company owns 100% of its common stock.
In other words, the parent company owns the company outright and there are no minority owners. , Nutraceutical Development Corporation (NDC NDC National Drug Code
NDC NATO Defense College
NDC National Documentation Centre (National Hellenic Research Foundation, Athens, Greece)
NDC National Dairy Council
NDC National Democratic Congress ), licensed the technology to Basic Research to develop and market a non-steroid supplement which utilizes the Company's muscle mass technology. Endothil-CR is currently available at GNC GNC General Nutrition Centers
GNC Gas Natural Comprimido (Argentina)
GNC Guidance, Navigation, and Control
GNC Grand National Championship (ATV racing)
GNC Global Navigation Chart stores nationwide or on the World Wide Web at www.Endothil.com.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit www.endovasc.com.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.